EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia

Ya-Feng Wen iD, Richard C Brundage, Youssef M Roman iD, Kathleen A Culhane-Pera, Robert J Straka iD

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Ya-Feng Wen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Hyperuricemia, Gout, Organic Anion Transporters. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, University of Minnesota, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of this study was to quantify identifiable sources of variability, including key pharmacogenetic variants in oxypurinol pharmacokinetics and their pharmacodynamic effect on serum urate (SU).

Methods

Hmong participants ( n = 34) received 100 mg allopurinol twice daily for 7 days followed by 150 mg allopurinol twice daily for 7 days. A sequential population pharmacokinetic pharmacodynamics (PKPD) analysis with non‐linear mixed effects modelling was performed. Allopurinol maintenance dose to achieve target SU was simulated based on the final PKPD model.

Results

A one‐compartment model with first‐order absorption and elimination best described the oxypurinol concentration–time data. Inhibition of SU by oxypurinol was described with a direct inhibitory E max model using steady‐state oxypurinol concentrations. Fat‐free body mass, estimated creatinine clearance and SLC22A12 rs505802 genotype (0.32 per T allele, 95% CI 0.13, 0.55) were found to predict differences in oxypurinol clearance. Oxypurinol concentration required to inhibit 50% of xanthine dehydrogenase activity was affected by PDZK1 rs12129861 genotype (−0.27 per A allele, 95% CI −0.38, −0.13). Most individuals with both PDZK1 rs12129861 AA and SLC22A12 rs505802 CC genotypes achieve target SU (with at least 75% success rate) with allopurinol below the maximum dose, regardless of renal function and body mass. In contrast, individuals with both PDZK1 rs12129861 GG and SLC22A12 rs505802 TT genotypes would require more than the maximum dose, thus requiring selection of alternative medications.

Conclusions

The proposed allopurinol dosing guide uses individuals' fat‐free mass, renal function and SLC22A12 rs505802 and PDZK1 rs12129861 genotypes to achieve target SU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaGoutOrganic Anion TransportersAdultHumansOxypurinolAllopurinolGout SuppressantsPharmacogeneticsOrganic Cation Transport Proteins

Stichwörter der Autor:innen

NONMEMallopurinolgoutpharmacometricspopulation pharmacokinetics

Substanzen

OxypurinolAllopurinolGout SuppressantsSLC22A12 protein, humanOrganic Anion TransportersOrganic Cation Transport Proteins

Autor:innen und Institutionen

  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Minnesota Community Care, St. Paul, Minnesota, USA.

ORCID-Profile: Ya-Feng Wen, Youssef M Roman, Robert J Straka

Förderung

  • NCATS NIH HHS
  • University of Minnesota
  • National Institutes of Health

Zitieren

APA

Wen, Y. F., Brundage, R. C., Roman, Y. M., Culhane-Pera, K. A., & Straka, R. J. (2023). Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15792

Vancouver

Wen YF, Brundage RC, Roman YM, Culhane-Pera KA, Straka RJ. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15792

BibTeX
@article{Wen2023,
  author = {Wen, Ya-Feng and Brundage, Richard C and Roman, Youssef M and Culhane-Pera, Kathleen A and Straka, Robert J},
  title = {Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15792}
}
Kostenlos starten →